Nervgen Pharma (NGEN) Receivables (2024 - 2026)

Nervgen Pharma (NGEN) has reported Receivables for 3 consecutive years, with $144755.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $144755.7 in Q2 2026; TTM through Jun 2026 was $144755.7, a N/A change from a year earlier, with the FY2025 full-year figure at $57958.5, down 80.89% from the prior year.
• Receivables was $144755.7 for Q2 2026 at Nervgen Pharma, up from $68206.3 in the prior quarter.
• Over five years, Receivables peaked at $297292.9 in Q4 2024 and troughed at $57958.5 in Q4 2025.
• A 3-year average of $142053.3 and a median of $106481.0 in 2026 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 80.5% in 2025, down 80.5% in 2025.
• Over 3 years, Receivables stood at $297292.9 in 2024, then slumped by 80.5% to $57958.5 in 2025, then jumped by 149.76% to $144755.7 in 2026.
• The last three Receivables figures came in at $144755.7 (Q2 2026), $68206.3 (Q1 2026), and $57958.5 (Q4 2025), per Business Quant data.